Shots:

• Merck KGaA discontinues its P-II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine + cisplatin in patients with locally advanced or metastatic BTC
• The discontinuation is based on the IDMC’s recommendation following a review of data which concluded that the trial fails to meet the primary objective of OS & no new safety signals were observed
• Bintrafusp alfa (M7824) is a bifunctional fusion protein targeting TGF-β and PD-L1. The therapy is currently in clinical development under collaboration with GSK

Ref: Merck KGaA | Image: Merck KGaA